Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 19/20 | 0.74 |
| ▸ | JAK1 | P23458 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25537133 | 0.94 | TYK2 (0.66) | TYK2 | |
| SCHEMBL30260243 | 0.92 | TYK2 (0.79) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30227425 | 0.90 | TYK2 (0.71) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30227537 | 0.89 | TYK2 (0.77) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30227365 | 0.89 | TYK2 (0.70) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30260248 | 0.88 | TYK2 (0.73) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30260207 | 0.86 | TYK2 (0.81) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL25537143 | 0.86 | TYK2 (0.70) | TYK2 | |
| SCHEMBL30227477 | 0.86 | TYK2 (0.71) | TYK2JAK1CYP2C19UGT1A1KCNH2 | |
| SCHEMBL30227556 | 0.86 | TYK2 (0.71) | TYK2JAK1CYP2C19UGT1A1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | claimed |
| CN-115715287-A | Substituted N- (methyl-d 3) pyridazine-3-carboxamide or N- (methyl-d 3) -nicotinamide compounds as IL-12, IL-23 and/or IFN alpha modulators | 百时美施贵宝公司 | 2023-02-24 | — | — | CN | claimed |
| EP-4143180-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | Bristol-Myers Squibb Company (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115715287-A | Substituted N- (methyl-d 3) pyridazine-3-carboxamide or N- (methyl-d 3) -nicotinamide compounds as IL-12, IL-23 and/or IFN alpha modulators | 百时美施贵宝公司 | 2023-02-24 | — | — | CN | disclosed |